Table 2 Summarized of grade 3 or greater adverse events
Outcomes | NAC group | Control group | RR (95% CI) | P value | P value for heterogeneity |
|---|---|---|---|---|---|
Granulocytopenia | 67/222 | 52/240 | 1.23 (0.81–1.87) | 0.338 | 0.209 |
Lymphocytopenia | 46/204 | 23/230 | 2.02 (1.27–3.24) | 0.003 | – |
Leukopenia | 39/250 | 29/263 | 1.26 (0.59–2.66) | 0.552 | 0.086 |
Hemoglobinopathy | 11/239 | 1/252 | 11.13 (1.45–85.58) | 0.021 | – |
Thrombocytopenia | 2/287 | 6/286 | 0.35 (0.07–1.72) | 0.195 | 0.677 |
Other hematologic abnormality | 1/249 | 2/251 | 0.51 (0.05–5.55) | 0.577 | – |
Nausea | 25/264 | 29/263 | 0.86 (0.53–1.41) | 0.559 | 0.889 |
Vomiting | 13/237 | 14/239 | 0.94 (0.45–1.96) | 0.868 | – |
Neurologic effects | 10/279 | 7/285 | 1.46 (0.55–3.89) | 0.453 | 0.329 |
Skin effects | 8/242 | 2/251 | 4.05 (0.87–18.88) | 0.075 | – |
Stomatitis | 10/240 | 5/248 | 2.02 (0.70–5.84) | 0.192 | – |
Diarrhea | 6/244 | 5/248 | 1.21 (0.38–3.93) | 0.746 | – |